{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T21:59:46Z","timestamp":1778795986714,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Environmental Toxicology and Pharmacology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.etap.2012.04.004","type":"journal-article","created":{"date-parts":[[2012,4,10]],"date-time":"2012-04-10T21:37:24Z","timestamp":1334093844000},"page":"223-227","source":"Crossref","is-referenced-by-count":5,"title":["Transepithelial transport of biperiden hydrochloride in Caco-2 cell monolayers"],"prefix":"10.1016","volume":"34","author":[{"given":"Ivana S.","family":"Abalos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanina I.","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Cereseto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria V.","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta E.","family":"Spinetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos","family":"Chiale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Pesce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.etap.2012.04.004_bib0005","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.etap.2012.04.004_bib0140","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/0006-291X(91)91647-U","article-title":"Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells","volume":"175","author":"Artursson","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.etap.2012.04.004_bib0010","series-title":"XLVI Congreso Argentino de Neurolog\u00eda. Mar del Plata","article-title":"Incidencia y prevalencia de la enfermedad de parkinson","author":"Bauso","year":"2009"},{"key":"10.1016\/j.etap.2012.04.004_bib0015","first-page":"171","article-title":"Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2","volume":"288","author":"Collett","year":"1999","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.etap.2012.04.004_bib0020","series-title":"Disposici\u00f3n No. 758. Criterios de Bioexenci\u00f3n de Estudios de Bioequivalencia para medicamentos s\u00f3lidos orales de liberaci\u00f3n inmediata","author":"ANMAT","year":"2009"},{"key":"10.1016\/j.etap.2012.04.004_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jnci\/59.1.221","article-title":"One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice","volume":"59","author":"Fogh","year":"1977","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.etap.2012.04.004_bib0030","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/BF00615970","article-title":"Pharmacokinetic and pharmacodynamic studies following the intravenous and oral administration of the antiparkinsonian drug biperiden to normal subjects","volume":"29","author":"Grimaldi","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.etap.2012.04.004_bib0035","series-title":"Bioanalytical Method Validation","article-title":"Guidance for Industry","author":"CDER\/FDA","year":"2001"},{"key":"10.1016\/j.etap.2012.04.004_bib0040","series-title":"Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutical Classification System","article-title":"Guidance for industry","author":"CDER\/FDA","year":"2000"},{"key":"10.1016\/j.etap.2012.04.004_bib0045","series-title":"Guideline on the Investigation of Bioequivalence","author":"EMEA","year":"2008"},{"key":"10.1016\/j.etap.2012.04.004_bib0050","first-page":"525","article-title":"Absolute bioavailability of oral theophylline","volume":"34","author":"Hendeles","year":"1977","journal-title":"Am. J. Hosp. Pharm."},{"key":"10.1016\/j.etap.2012.04.004_bib0055","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1038\/nprot.2007.303","article-title":"Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers","volume":"2","author":"Hubatsch","year":"2007","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.etap.2012.04.004_bib0060","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1021\/js9803205","article-title":"MDCK (Madin\u2013Darby canine kidney) cells: a tool for membrane permeability screening","volume":"88","author":"Irvine","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.etap.2012.04.004_bib0065","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1021\/mp034006h","article-title":"Molecular properties of WHO essential drugs and provisional biopharmaceutical classification","volume":"12","author":"Kasim","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.etap.2012.04.004_bib0070","doi-asserted-by":"crossref","first-page":"645","DOI":"10.2174\/138920007782109823","article-title":"Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans","volume":"8","author":"Lennern\u00e4s","year":"2007","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.etap.2012.04.004_bib0075","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2004.03.001","article-title":"Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the biopharmaceutics classification system","volume":"58","author":"Lindenberg","year":"2004","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.etap.2012.04.004_bib0080","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1124\/jpet.102.039255","article-title":"Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs","volume":"303","author":"Mahar Doan","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.etap.2012.04.004_bib0085","series-title":"The Complete Drug Reference","first-page":"479","author":"Martindale","year":"2005"},{"key":"10.1016\/j.etap.2012.04.004_bib0090","first-page":"33","article-title":"Standardization of Caco-2 cell culture as in vitro model for intestinal permeability","volume":"30","author":"Rodr\u00edguez","year":"2011","journal-title":"Lat. Am. J. Pharmacol."},{"key":"10.1016\/j.etap.2012.04.004_bib0095","series-title":"Poster Presented at the AAPS Annual Meeting 2002","article-title":"Examination of the MDCK-II cell as an intestinal model for permeability screening","author":"Spicer","year":"2002"},{"key":"10.1016\/j.etap.2012.04.004_bib0100","series-title":"Therapeutic Drugs","year":"1991"},{"key":"10.1016\/j.etap.2012.04.004_bib0105","series-title":"\u30081225\u3009 General Chapter: Validation of Compendial Methods","author":"USP 32-NF 27","year":"2009"},{"key":"10.1016\/j.etap.2012.04.004_bib0110","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1021\/mp0499196","article-title":"Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport","volume":"2","author":"Varma","year":"2005","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.etap.2012.04.004_bib0115","first-page":"665","article-title":"Drug permeability studies in regulatory biowaiver applications","volume":"vol. VII, no. 5","author":"Volpe","year":"2008"},{"key":"10.1016\/j.etap.2012.04.004_bib0120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/10601330701273669","article-title":"Classification of drug permeability with a Caco-2 cell monolayer assay","volume":"24","author":"Volpe","year":"2007","journal-title":"Clin. Res. Regul. Aff."},{"key":"10.1016\/j.etap.2012.04.004_bib0125","unstructured":"World Health Organization, 2005. Proposal to waive in vivo bioequivalence requirements for the WHO model list of essential medicines immediate release, solid oral dosage forms. Working document QAS\/04.109\/Rev.1."},{"key":"10.1016\/j.etap.2012.04.004_bib0130","unstructured":"World Health Organization, 2006. Technical Report Series No. 937, Anexo 8. Proposal to waive in vivo bioequivalence requirements for WHO Model List of Essential. Medicines immediate-release, solid oral dosage forms."},{"key":"10.1016\/j.etap.2012.04.004_bib0135","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1023\/A:1012102522787","article-title":"In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in Man \u2013 Fact or Myth","volume":"14","author":"Yee","year":"1997","journal-title":"Pharm. Res."}],"container-title":["Environmental Toxicology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668912000610?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1382668912000610?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,24]],"date-time":"2018-11-24T06:24:22Z","timestamp":1543040662000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1382668912000610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S1382668912000610"],"URL":"https:\/\/doi.org\/10.1016\/j.etap.2012.04.004","relation":{},"ISSN":["1382-6689"],"issn-type":[{"value":"1382-6689","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}